This study is in collaboration with Osaka University Research Foundation for Microbial Diseases. The HA-antigen, habitually used in Japan, and LPS as an adjuvant are used. Novelty lies in that the vaccine is a tablet which is administered under the tongue and melts with saliva. It repels the invading virus and the virus itself induces this effect.

Nitto Denko news release, November 4, 2016